Nitroxide Pharmaceutical Development for Age-Related Degeneration and Disease

    November 2015 in “ Frontiers in Genetics
    Jacob A. Zarling, Vienna E. Brunt, Anne K. Vallerga, Weixing Li, Albert Tao, David A. Zarling, Christopher T. Minson
    TLDR Nitroxide drugs can safely and effectively treat age-related diseases like macular degeneration and cardiovascular issues.
    The document discussed the development of nitroxide-based pharmaceuticals, particularly Tempol (TP), Tempol Hydroxylamine (TP-H), and OT-551, for treating age-related macular degeneration (AMD) and cardiovascular disease (CVD). These drugs aimed to reduce oxidative stress and inflammation, with clinical trials showing that OT-551 preserved visual acuity in over 200 AMD patients without adverse events over up to 2 years. OT-551 also showed promise in preventing radiation-induced skin burns and hair loss in brain cancer patients. Tempol improved microvascular function in smokers. The findings supported further development of nitroxide agents for various age-related and smoking-related conditions.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results

    Related Community Posts Join

    0 / 0 results
    — no results

    Similar Research

    5 / 55 results